TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26775454

Group type: EXPERIMENTAL
Intervention: Pre-visit vaccination video education
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (no video education)
Number of subjects: 105
Study: 23680036

Group type: EXPERIMENTAL
Intervention: MIPS (multi-ingredient performance supplement)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (isocaloric maltodextrin)
Number of subjects: 24
Study: 21252092

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 132

Group type: COMPARATOR
Intervention: Allo-HSCT
Number of subjects: 132
Study: 18433709

Group type: EXPERIMENTAL
Intervention: Pink grapefruit juice
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 16271817

Group type: EXPERIMENTAL
Intervention: Event related brain potential (ERP) recordings during global-local reaction time task
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: P100 responses
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: N150 responses
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: P300 responses
Number of subjects: 30
Study: 15272967

Group type: EXPERIMENTAL
Intervention: Justice attitude (person factor) and responsibility for damage (situation factor)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Increasing negativity of attitude toward equality
Number of subjects: 80
Study: 11202339

Group type: EXPERIMENTAL
Intervention: Vestibular testing in children with migraine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group of 15 healthy children
Number of subjects: 20
Study: 8971437

Group type: EXPERIMENTAL
Intervention: Picotamide (900 mg day-1)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 438
Study: 1462531

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 16000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16000
Study: 6337405

Group type: EXPERIMENTAL
Intervention: 6 mg of guanabenz twice daily as well as hydrochlorothiazide
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo and hydrochlorothiazide
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Comparison of guanabenz and hydrochlorothiazide vs placebo and hydrochlorothiazide
Number of subjects: 25
Study: 31360445

Group type: EXPERIMENTAL
Intervention: WASH intervention (water supply, sanitation facilities, handwashing facilities, drinking water filters, behavior change education)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (comparison schools received the intervention after research activities ended)
Number of subjects: 100
Study: 30286797

Group type: EXPERIMENTAL
Intervention: Group education programme with text-message support over 12 months
Number of subjects: 290

Group type: COMPARATOR
Intervention: Standard care and a physical activity information leaflet
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Group-based structured education sessions
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Text-message support
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Secondary outcomes at 12 months
Number of subjects: 290
Study: 27195735

Group type: EXPERIMENTAL
Intervention: Minimalist shoes training for 6 months
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard shoes training for 6 months (Control)
Number of subjects: 38
Study: 24648302

Group type: EXPERIMENTAL
Intervention: Bioavailability-boosted curcuminoids preparation (180 mg/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 80
Study: 21786525

Group type: EXPERIMENTAL
Intervention: 100 mg ketoprofen administered intravenously one hour before the procedure and at 8, 24, 36 and 48 h after
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (0.9% saline) administered intravenously one hour before the procedure and at 8, 24, 36 and 48 h after
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups (ketoprofen and placebo)
Number of subjects: 52
Study: 19660897

Group type: EXPERIMENTAL
Intervention: Supervised exercise rehabilitation
Number of subjects: 217

Group type: COMPARATOR
Intervention: Invasive revascularization with stents
Number of subjects: 217
Study: 16735487

Group type: EXPERIMENTAL
Intervention: +MTZ
Number of subjects: 75

Group type: COMPARATOR
Intervention: ‐MTZ
Number of subjects: 75
Study: 15538130

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 31
Study: 11999818

Group type: EXPERIMENTAL
Intervention: Octreotide infusion for 48 hours
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Octreotide infusion for 48 hours plus 72 hours subcutaneous injection
Number of subjects: 43

Group type: COMPARATOR
Intervention: Octreotide infusion
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of octreotide for another 72 hours
Number of subjects: 43
Study: 9052320

Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: 0.9% Saline (Placebo)
Number of subjects: 150
Study: 7871060

Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 3540813

Group type: EXPERIMENTAL
Intervention: TENS treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo TENS treatment
Number of subjects: 18
Study: 1124809

Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide‐imipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31331564

Group type: EXPERIMENTAL
Intervention: Ranitidine plus quince syrup
Number of subjects: 96

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 96
Study: 28371141

Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard medical therapy for HFrEF alone
Number of subjects: 100
Study: 25040896

Group type: EXPERIMENTAL
Intervention: Lifestyle modification program
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (no lifestyle modification)
Number of subjects: 154
Study: 24383121

Group type: EXPERIMENTAL
Intervention: HM-ON (Home Monitoring ON)
Number of subjects: 151

Group type: COMPARATOR
Intervention: HM-OFF (Home Monitoring OFF)
Number of subjects: 151
Study: 22384549

Group type: EXPERIMENTAL
Intervention: Quantization diagnostic standard for IgA nephropathy of QYDS
Number of subjects: 1016
Study: 19375592

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg daily for 6 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 17276018

Group type: EXPERIMENTAL
Intervention: Immediate on-site vaccination availability
Number of subjects: 3181

Group type: EXPERIMENTAL
Intervention: Monetary incentives
Number of subjects: 3181

Group type: EXPERIMENTAL
Intervention: Vaccination willingness
Number of subjects: 3181

Group type: EXPERIMENTAL
Intervention: Vaccination uptake by site
Number of subjects: 3181

Group type: EXPERIMENTAL
Intervention: Anti-HAV and anti-HBc seroprevalence
Number of subjects: 3181
Study: 15611220

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention program (six modules in five weekly group sessions)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Comparison group (no specific intervention mentioned)
Number of subjects: 22
Study: 11275669

Group type: EXPERIMENTAL
Intervention: Fluoride and baking soda (F+NaHCO(3)) dentifrice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoride (F) dentifrice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 0
Study: 9011700

Group type: EXPERIMENTAL
Intervention: Complete metastasectomy
Number of subjects: 5206

Group type: COMPARATOR
Intervention: Incomplete metastasectomy
Number of subjects: 5206

Group type: EXPERIMENTAL
Intervention: Complete metastasectomy with disease-free interval of 0 to 11 months
Number of subjects: 5206

Group type: EXPERIMENTAL
Intervention: Complete metastasectomy with disease-free interval of more than 36 months
Number of subjects: 5206

Group type: EXPERIMENTAL
Intervention: Complete metastasectomy with single lesions
Number of subjects: 5206

Group type: EXPERIMENTAL
Intervention: Complete metastasectomy with four or more lesions
Number of subjects: 5206

Group type: EXPERIMENTAL
Intervention: Complete metastasectomy with germ cell tumors
Number of subjects: 5206

Group type: EXPERIMENTAL
Intervention: Complete metastasectomy with disease-free intervals of 36 months or more
Number of subjects: 5206

Group type: EXPERIMENTAL
Intervention: Complete metastasectomy with single metastases
Number of subjects: 5206
Study: 8275659

Group type: EXPERIMENTAL
Intervention: TUDCA (Tauro-ursodeoxycholic acid)
Number of subjects: 34

Group type: COMPARATOR
Intervention: UDCA (Ursodeoxycholic acid)
Number of subjects: 34
Study: 3430263

Group type: EXPERIMENTAL
Intervention: Biofeedback (B)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mineral oil therapy (M)
Number of subjects: 50
Study: 29843895

Group type: EXPERIMENTAL
Intervention: Posterior plating and anterior fixation with percutaneous anterior column screw (double column group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Posterior fixation alone (single column group)
Number of subjects: 30
Study: 26585287

Group type: EXPERIMENTAL
Intervention: LY2940094 (40 mg once daily for 8 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24742217

Group type: EXPERIMENTAL
Intervention: Telephone-based peer support (mother-to-mother) provided by trained peer volunteers.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned in the abstract.
Number of subjects: 0
Study: 23767831

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aflibercept (administered every 2 weeks)
Number of subjects: 0
Study: 20684981

Group type: EXPERIMENTAL
Intervention: Autograft aortic root replacement (Ross procedure)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Homograft aortic root replacement
Number of subjects: 216
Study: 18832884

Group type: EXPERIMENTAL
Intervention: Recombinant native HIV-1 Tat protein vaccine
Number of subjects: 0
Study: 17060350

Group type: EXPERIMENTAL
Intervention: Dietary change intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 15147494

Group type: EXPERIMENTAL
Intervention: Cognitive heading during imagined locomotion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perceived heading during imagined locomotion
Number of subjects: 0
Study: 10934807

Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure (BiPAP) via nasal or facial mask
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PLV‐100 via nasal or facial mask
Number of subjects: 12
Study: 9059204

Group type: EXPERIMENTAL
Intervention: Abdominal wall elevation (AWE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Carbon dioxide pneumoperitoneum (PN)
Number of subjects: 20
Study: 7908147

Group type: EXPERIMENTAL
Intervention: Parlodel (bromocriptine) fast titration (15 mg/day for 3 weeks)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Parlodel (bromocriptine) slow titration (15 mg/day for 5 weeks)
Number of subjects: 153
Study: 3593985

Group type: EXPERIMENTAL
Intervention: Tamoxifen (T) alone or T in combination with medroxyprogesterone acetate, diethylstilbestrol, halotestin, or aminoglutethimide
Number of subjects: 465
Study: 28380705

Group type: EXPERIMENTAL
Intervention: Integrated Attention Training Program (IATP)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Health-related education program (active control group)
Number of subjects: 93
Study: 26945956

Group type: EXPERIMENTAL
Intervention: Anatomic fovea landmark technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: C-arm technique
Number of subjects: 0
Study: 24708917

Group type: EXPERIMENTAL
Intervention: Selenium (60 μg/d, as Se-enriched yeast)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 22291058

Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 0
Study: 20555331

Group type: EXPERIMENTAL
Intervention: 80 mg day(-1) valsartan
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: 160 mg day(-1) valsartan
Number of subjects: 181
Study: 18525061

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 25) received an information sheet on coping-promoting talk.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (n = 25) received standard care.
Number of subjects: 50
Study: 16759447

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) including Salvia miltiorrhiza, Acanthopanax senticosus, Ginkgo biloba, Pueraria lobata, Liguisticum chuanxiong, cow bezoar, Diospyros kaki, Gynostemma pentaphyllum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium antagonists
Number of subjects: 0
Study: 12627988

Group type: EXPERIMENTAL
Intervention: Nasal budesonide 128 microg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal budesonide 128 microg twice daily after polypectomy
Number of subjects: 0
Study: 10356887

Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve YIT4064, 50 mg daily for 28 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve YIT4064
Number of subjects: 19
Study: 8910175

Group type: EXPERIMENTAL
Intervention: Mild hemodilution (Hct 31%)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Moderate hemodilution (Hct 23%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no hemodilution)
Number of subjects: 20
Study: 2065844

Group type: EXPERIMENTAL
Intervention: Low dose cisplatin (50 mg/m2) with short treatment regimen (6 months)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low dose cisplatin (50 mg/m2) with extended treatment regimen (12 months)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low dose cisplatin (50 mg/m2) with treatment in blocks (intervening months without cisplatin)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High dose cisplatin (100 mg/m2) with short treatment regimen (6 months)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High dose cisplatin (100 mg/m2) with extended treatment regimen (12 months)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High dose cisplatin (100 mg/m2) with treatment in blocks (intervening months without cisplatin)
Number of subjects: 60
Study: 6359947

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 33

Group type: COMPARATOR
Intervention: ZEEP
Number of subjects: 33
Study: 30389899

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (ET)
Number of subjects: 0
Study: 29666026

Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Checkpoint inhibitors (nivolumab, pembrolizumab, cemiplimab)
Number of subjects: 0
Study: 27682034

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg intravenous)
Number of subjects: 2013

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2013
Study: 24492452

Group type: EXPERIMENTAL
Intervention: Isometric contraction of the elbow flexor muscles
Number of subjects: 15

Group type: COMPARATOR
Intervention: Quiet rest
Number of subjects: 15
Study: 22119935

Group type: EXPERIMENTAL
Intervention: levodopa (200 mg) / benserazide (50 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study: 20713668

Group type: EXPERIMENTAL
Intervention: 300 mg peramivir
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 600 mg peramivir
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 17555171

Group type: EXPERIMENTAL
Intervention: Alert Condensable (Jeneric/Pentron)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SureFil (Dentsply/Caulk)
Number of subjects: 50
Study: 15880313

Group type: EXPERIMENTAL
Intervention: Oligofructose
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 12084163

Group type: EXPERIMENTAL
Intervention: Plasma-removed platelets
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Whole blood-derived prestorage WBC-reduced platelets
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Prestorage WBC-reduced apheresis platelets
Number of subjects: 129

Group type: COMPARATOR
Intervention: Overall frequency of reactions
Number of subjects: 129
Study: 9863850

Group type: EXPERIMENTAL
Intervention: Biofeedback‐assisted behavioral treatment
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Drug treatment (oxybutynin chloride, 2.5 mg daily to 5.0 mg 3 times daily)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 197
Study: 8721904

Group type: EXPERIMENTAL
Intervention: Rifampicin in addition to isoniazid, pyrazinamide and ethambutol
Number of subjects: 180

Group type: COMPARATOR
Intervention: No rifampicin
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: All four drugs (rifampicin, isoniazid, pyrazinamide, ethambutol) for younger patients
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Higher mean concentrations of hydrazine, rifampicin and pyrazinamide
Number of subjects: 180
Study: 1694593

Group type: EXPERIMENTAL
Intervention: Fenoterol (2 inhalations every 5 hours)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (2 inhalations every 5 hours)
Number of subjects: 6
Study: 399315

Group type: EXPERIMENTAL
Intervention: Ethynyl oestradiol‐50 micron/day
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Levonorgestrel‐250 micron/day
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Nordial (combination of ethynyl oestradiol and levonorgestrel)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 31272334

Group type: EXPERIMENTAL
Intervention: Intervention video only
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Intervention video with discussion
Number of subjects: 294

Group type: COMPARATOR
Intervention: Attentional control video
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Intervention video (both conditions)
Number of subjects: 294
Study: 28972045

Group type: EXPERIMENTAL
Intervention: Perioperative ECF chemotherapy
Number of subjects: 456

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 456
Study: 25185211

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Best medical therapy (BMT)
Number of subjects: 280
Study: 24628884

Group type: EXPERIMENTAL
Intervention: Telephone Monitoring (TM; N=83)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Telephone Monitoring and Brief Counseling (TMC; N=83)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Treatment as Usual (Control)
Number of subjects: 252
Study: 22873758

Group type: EXPERIMENTAL
Intervention: Intramuscular injections of botulinum toxin A (BoNT‐A) combined with standard therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 40
Study: 19387391

Group type: EXPERIMENTAL
Intervention: Seated Wingate test 1 (WinD1)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Seated Wingate test 2 (WinD2)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Seated Wingate test 3 (WinD3)
Number of subjects: 7
Study: 17690191

Group type: EXPERIMENTAL
Intervention: Intermittent hypobaric hypoxia (IHE, 3 h/day, 5 days/wk at 4,000‐5,500 m)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normobaric normoxia (Control group)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intermittent hypobaric hypoxia (IHE) for swimmers
Number of subjects: 23
Study: 15764114

Group type: EXPERIMENTAL
Intervention: Epiphora patients
Number of subjects: 96

Group type: COMPARATOR
Intervention: Second-eye cataract patients
Number of subjects: 96
Study: 12090633

Group type: EXPERIMENTAL
Intervention: Orthogonal Astigmatism Test (OAT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Jackson Crossed-Cylinder (JCC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Raubitschek Arrow (RA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fan and Block (FB)
Number of subjects: 50
Study: 9839623

Group type: EXPERIMENTAL
Intervention: Hyaluronidase as an additive to chemotherapy and radiation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy and radiation therapy without hyaluronidase
Number of subjects: 0
Study: 7983236

Group type: EXPERIMENTAL
Intervention: 200 mg dose of loracarbef
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 400 mg dose of loracarbef
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 200 mg dose of loracarbef (women)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 400 mg dose of loracarbef (women)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: loracarbef
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: loracarbef (400 mg dose)
Number of subjects: 20
Study: 2499588

Group type: EXPERIMENTAL
Intervention: 10,000 IU hCG
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study: 31429629

Group type: EXPERIMENTAL
Intervention: Basic gel containing 3%(w/w)-TTO
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Advanced gel containing 3%(w/w)-TTO plus essential oils and vitamins
Number of subjects: 49
Study: 29560955

Group type: EXPERIMENTAL
Intervention: Early operative treatment (12‐hour medication)
Number of subjects: 703

Group type: COMPARATOR
Intervention: Long‐term conservative treatment (48 hours)
Number of subjects: 703
Study: 27075843

Group type: EXPERIMENTAL
Intervention: Household and personal cleaning products (microbicides triclosan and triclocarban)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Weekly surveys
Number of subjects: 158
Study: 22961838

Group type: EXPERIMENTAL
Intervention: ECHO (guided self-help intervention for carers)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual only
Number of subjects: 0
Study: 20942668

Group type: EXPERIMENTAL
Intervention: Tanezumab (10, 25, 50, 100, or 200 μg/kg)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Tanezumab
Number of subjects: 450
Study: 18219181

Group type: EXPERIMENTAL
Intervention: Raloxifene plus Alfacalcidol (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Raloxifene alone (Group B)
Number of subjects: 60
Study: 16845627

Group type: EXPERIMENTAL
Intervention: Aventis Pasteur smallpox vaccine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 74